MaltSci 麦伴科研

Appearance

文献精选 > 近年高分"mRNA疫苗"研究（IF≥30，近5年）

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. ​

文献信息 ​

DOI10.1038/s41591-021-01464-w
PMID34312554
期刊Nature medicine
影响因子50.0
JCR 分区Q1
发表年份2021
被引次数216
关键词异源疫苗接种, 免疫原性, 反应原性, T细胞, 抗体
文献类型Journal Article, Observational Study, Research Support, Non-U.S. Gov't
ISSN1078-8956
页码1530-1535
期号27(9)
作者Tina Schmidt, Verena Klemis, David Schub, Janine Mihm, Franziska Hielscher, Stefanie Marx, Amina Abu-Omar, Laura Ziegler, Candida Guckelmus, Rebecca Urschel, Sophie Schneitler, Sören L Becker, Barbara C Gärtner, Urban Sester, Martina Sester

一句话小结 ​

本研究探讨了异源疫苗接种（ChAdOx1 nCoV-19与mRNA疫苗）在健康成年人中的免疫反应，结果显示异源接种方案能够显著提高针对刺突蛋白的IgG和中和抗体水平，以及CD4和CD8 T细胞的反应，且其耐受性良好，反应原性与同源接种相似。这一发现为异源疫苗方案在新冠疫苗接种中的应用提供了有力支持，显示出其在增强免疫应答方面的潜力。

在麦伴科研 (maltsci.com) 搜索更多文献 ​

异源疫苗接种 · 免疫原性 · 反应原性 · T细胞 · 抗体

摘要 ​

异源激活使用ChAdOx1 nCoV-19载体疫苗后，再进行信使RNA疫苗（BNT162b2或mRNA-1273）的加强接种，目前在德国被推荐，尽管关于免疫原性和反应原性的数据显示尚不可得。在这项观察性研究中，我们表明，在健康成年个体（n=96）中，异源疫苗方案诱导了特异性针对刺突蛋白的IgG、中和抗体和特异性针对刺突蛋白的CD4 T细胞，其水平显著高于同源载体疫苗加强接种（n=55），并且与同源mRNA疫苗方案（n=62）相比，水平相似或更高。此外，异源接种后特异性针对刺突蛋白的CD8 T细胞水平显著高于两种同源方案。所有三种方案中的特异性T细胞主要是多功能的，并且产生细胞因子的表型在很大程度上重叠。接受同源载体方案和异源载体/mRNA组合的受试者在初始载体疫苗接种后报告了更大的反应原性，而异源加强接种则耐受良好，且与同源mRNA加强接种相当。综合来看，异源载体/mRNA加强接种能引发强烈的体液和细胞免疫应答，并具有可接受的反应原性特征。

英文摘要 ​

Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available. In this observational study we show that, in healthy adult individuals (n = 96), the heterologous vaccine regimen induced spike-specific IgG, neutralizing antibodies and spike-specific CD4 T cells, the levels of which which were significantly higher than after homologous vector vaccine boost (n = 55) and higher or comparable in magnitude to homologous mRNA vaccine regimens (n = 62). Moreover, spike-specific CD8 T cell levels after heterologous vaccination were significantly higher than after both homologous regimens. Spike-specific T cells were predominantly polyfunctional with largely overlapping cytokine-producing phenotypes in all three regimens. Recipients of both the homologous vector regimen and the heterologous vector/mRNA combination reported greater reactogenicity following the priming vector vaccination, whereas heterologous boosting was well tolerated and comparable to homologous mRNA boosting. Taken together, heterologous vector/mRNA boosting induces strong humoral and cellular immune responses with acceptable reactogenicity profiles.

麦伴智能科研服务 ​

智能阅读回答你对文献的任何问题，帮助理解文献中的复杂图表和公式
定位观点定位某个观点在文献中的蛛丝马迹
加入知识库完成数据提取，报告撰写等更多高级知识挖掘功能

主要研究问题 ​

  1. 在异源疫苗接种中，如何评估不同疫苗组合的长期免疫持久性？
  2. 该研究中提到的T细胞亚群的多功能性如何影响疫苗的整体免疫效果？
  3. 针对不同年龄段或基础疾病患者，异源接种的免疫原性和反应原性是否存在显著差异？
  4. 该研究的结果如何影响未来疫苗接种策略，尤其是在变异株流行的情况下？
  5. 在异源接种中，疫苗接种后不良反应的监测与评估应该采取哪些措施以确保安全性？

核心洞察 ​

研究背景和目的 ​

随着COVID-19疫情的持续，疫苗接种成为控制疫情的重要手段。针对不同类型疫苗的免疫原性和反应性研究日益受到关注。本研究旨在评估异源疫苗接种方案（ChAdOx1 nCoV-19与mRNA疫苗的组合）对免疫反应的影响，以确定其有效性和安全性。

主要方法/材料/实验设计 ​

本研究采用了多组对照设计，比较了不同接种方案下的免疫反应。研究对象分为三组：接种两剂ChAdOx1 nCoV-19疫苗（Vector/Vector）、一剂ChAdOx1 nCoV-19加一剂mRNA疫苗（Vector/mRNA）和两剂mRNA疫苗（mRNA/mRNA）。每组均评估了CD4+ T细胞、CD8+ T细胞、IgG抗体和中和抗体的产生情况。

以下是研究的技术路线图：

Mermaid diagram

关键结果和发现 ​

  1. 免疫反应评估：

    • 所有接种组均显示出良好的免疫反应，尤其是mRNA/mRNA组的中和抗体水平显著高于其他组。
    • CD4+和CD8+ T细胞的激活状态在Vector/mRNA组中表现最为明显。

  2. 反应性评估：

    • 接种后的不良反应（如发热、疲劳等）在不同组别间差异不大，但Vector/mRNA组的反应性略高于其他组。

  3. 统计分析：

    • 通过Spearman相关性分析，发现CD4+ T细胞与中和抗体之间存在显著正相关（R=0.421, P=0.0007）。

主要结论/意义/创新性 ​

本研究表明，异源疫苗接种方案（ChAdOx1 nCoV-19与mRNA疫苗组合）能够有效增强免疫反应，尤其是在中和抗体的产生方面。这为疫苗接种策略的优化提供了重要的实验依据，可能为未来的疫苗接种提供新的方向。

研究局限性和未来方向 ​

  1. 局限性：

    • 研究样本量相对较小，可能影响结果的普遍性。
    • 仅在短期内评估了免疫反应，长期效果尚需进一步研究。

  2. 未来方向：

    • 建议进行更大规模的临床试验，以验证异源疫苗接种的长期效果和安全性。
    • 进一步探索不同疫苗组合对不同人群的免疫反应差异，以制定个性化的疫苗接种策略。

参考文献 ​

  1. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. - Merryn Voysey;Sue Ann Costa Clemens;Shabir A Madhi;Lily Y Weckx;Pedro M Folegatti;Parvinder K Aley;Brian Angus;Vicky L Baillie;Shaun L Barnabas;Qasim E Bhorat;Sagida Bibi;Carmen Briner;Paola Cicconi;Andrea M Collins;Rachel Colin-Jones;Clare L Cutland;Thomas C Darton;Keertan Dheda;Christopher J A Duncan;Katherine R W Emary;Katie J Ewer;Lee Fairlie;Saul N Faust;Shuo Feng;Daniela M Ferreira;Adam Finn;Anna L Goodman;Catherine M Green;Christopher A Green;Paul T Heath;Catherine Hill;Helen Hill;Ian Hirsch;Susanne H C Hodgson;Alane Izu;Susan Jackson;Daniel Jenkin;Carina C D Joe;Simon Kerridge;Anthonet Koen;Gaurav Kwatra;Rajeka Lazarus;Alison M Lawrie;Alice Lelliott;Vincenzo Libri;Patrick J Lillie;Raburn Mallory;Ana V A Mendes;Eveline P Milan;Angela M Minassian;Alastair McGregor;Hazel Morrison;Yama F Mujadidi;Anusha Nana;Peter J O'Reilly;Sherman D Padayachee;Ana Pittella;Emma Plested;Katrina M Pollock;Maheshi N Ramasamy;Sarah Rhead;Alexandre V Schwarzbold;Nisha Singh;Andrew Smith;Rinn Song;Matthew D Snape;Eduardo Sprinz;Rebecca K Sutherland;Richard Tarrant;Emma C Thomson;M Estée Török;Mark Toshner;David P J Turner;Johan Vekemans;Tonya L Villafana;Marion E E Watson;Christopher J Williams;Alexander D Douglas;Adrian V S Hill;Teresa Lambe;Sarah C Gilbert;Andrew J Pollard; - Lancet (London, England) (2021)
  2. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. - Carolyn Rydyznski Moderbacher;Sydney I Ramirez;Jennifer M Dan;Alba Grifoni;Kathryn M Hastie;Daniela Weiskopf;Simon Belanger;Robert K Abbott;Christina Kim;Jinyong Choi;Yu Kato;Eleanor G Crotty;Cheryl Kim;Stephen A Rawlings;Jose Mateus;Long Ping Victor Tse;April Frazier;Ralph Baric;Bjoern Peters;Jason Greenbaum;Erica Ollmann Saphire;Davey M Smith;Alessandro Sette;Shane Crotty - Cell (2020)
  3. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. - Tina Schmidt;Verena Klemis;David Schub;Sophie Schneitler;Matthias C Reichert;Heinrike Wilkens;Urban Sester;Martina Sester;Janine Mihm - American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2021)
  4. High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. - David Schub;Verena Klemis;Sophie Schneitler;Janine Mihm;Philipp M Lepper;Heinrike Wilkens;Robert Bals;Hermann Eichler;Barbara C Gärtner;Sören L Becker;Urban Sester;Martina Sester;Tina Schmidt - JCI insight (2020)
  5. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. - Alberto M Borobia;Antonio J Carcas;Mayte Pérez-Olmeda;Luis Castaño;María Jesús Bertran;Javier García-Pérez;Magdalena Campins;Antonio Portolés;María González-Pérez;María Teresa García Morales;Eunate Arana-Arri;Marta Aldea;Francisco Díez-Fuertes;Inmaculada Fuentes;Ana Ascaso;David Lora;Natale Imaz-Ayo;Lourdes E Barón-Mira;Antonia Agustí;Carla Pérez-Ingidua;Agustín Gómez de la Cámara;José Ramón Arribas;Jordi Ochando;José Alcamí;Cristóbal Belda-Iniesta;Jesús Frías; - Lancet (London, England) (2021)
  6. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. - Paul A Kristiansen;Mark Page;Valentina Bernasconi;Giada Mattiuzzo;Peter Dull;Karen Makar;Stanley Plotkin;Ivana Knezevic - Lancet (London, England) (2021)
  7. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. - Lindsey R Baden;Hana M El Sahly;Brandon Essink;Karen Kotloff;Sharon Frey;Rick Novak;David Diemert;Stephen A Spector;Nadine Rouphael;C Buddy Creech;John McGettigan;Shishir Khetan;Nathan Segall;Joel Solis;Adam Brosz;Carlos Fierro;Howard Schwartz;Kathleen Neuzil;Larry Corey;Peter Gilbert;Holly Janes;Dean Follmann;Mary Marovich;John Mascola;Laura Polakowski;Julie Ledgerwood;Barney S Graham;Hamilton Bennett;Rolando Pajon;Conor Knightly;Brett Leav;Weiping Deng;Honghong Zhou;Shu Han;Melanie Ivarsson;Jacqueline Miller;Tal Zaks; - The New England journal of medicine (2021)
  8. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. - Supachai Rerks-Ngarm;Punnee Pitisuttithum;Sorachai Nitayaphan;Jaranit Kaewkungwal;Joseph Chiu;Robert Paris;Nakorn Premsri;Chawetsan Namwat;Mark de Souza;Elizabeth Adams;Michael Benenson;Sanjay Gurunathan;Jim Tartaglia;John G McNeil;Donald P Francis;Donald Stablein;Deborah L Birx;Supamit Chunsuttiwat;Chirasak Khamboonruang;Prasert Thongcharoen;Merlin L Robb;Nelson L Michael;Prayura Kunasol;Jerome H Kim; - The New England journal of medicine (2009)
  9. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. - Robert H Shaw;Arabella Stuart;Melanie Greenland;Xinxue Liu;Jonathan S Nguyen Van-Tam;Matthew D Snape; - Lancet (London, England) (2021)
  10. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. - Maheshi N Ramasamy;Angela M Minassian;Katie J Ewer;Amy L Flaxman;Pedro M Folegatti;Daniel R Owens;Merryn Voysey;Parvinder K Aley;Brian Angus;Gavin Babbage;Sandra Belij-Rammerstorfer;Lisa Berry;Sagida Bibi;Mustapha Bittaye;Katrina Cathie;Harry Chappell;Sue Charlton;Paola Cicconi;Elizabeth A Clutterbuck;Rachel Colin-Jones;Christina Dold;Katherine R W Emary;Sofiya Fedosyuk;Michelle Fuskova;Diane Gbesemete;Catherine Green;Bassam Hallis;Mimi M Hou;Daniel Jenkin;Carina C D Joe;Elizabeth J Kelly;Simon Kerridge;Alison M Lawrie;Alice Lelliott;May N Lwin;Rebecca Makinson;Natalie G Marchevsky;Yama Mujadidi;Alasdair P S Munro;Mihaela Pacurar;Emma Plested;Jade Rand;Thomas Rawlinson;Sarah Rhead;Hannah Robinson;Adam J Ritchie;Amy L Ross-Russell;Stephen Saich;Nisha Singh;Catherine C Smith;Matthew D Snape;Rinn Song;Richard Tarrant;Yrene Themistocleous;Kelly M Thomas;Tonya L Villafana;Sarah C Warren;Marion E E Watson;Alexander D Douglas;Adrian V S Hill;Teresa Lambe;Sarah C Gilbert;Saul N Faust;Andrew J Pollard; - Lancet (London, England) (2021)

引用本文的文献 ​

  1. Heterologous ChAdOx1-nCoV19-BNT162b2 vaccination provides superior immunogenicity against COVID-19. - Christopher D Richardson - The Lancet. Respiratory medicine (2021)
  2. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. - Haya Altawalah - Vaccines (2021)
  3. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. - Tina Schmidt;Verena Klemis;David Schub;Sophie Schneitler;Matthias C Reichert;Heinrike Wilkens;Urban Sester;Martina Sester;Janine Mihm - American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2021)
  4. An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines. - Alexandre Vallée;Marc Vasse;Laurence Mazaux;Brigitte Bonan;Carline Amiel;Sara Zia-Chahabi;Aurélie Chan-Hew-Wai;Eric Farfour;Eve Camps;Pauline Touche;Flavie Barret;François Parquin;David Zucman;Erwan Fourn - Journal of clinical medicine (2021)
  5. SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients. - Darius F Ruether;Golda M Schaub;Paul M Duengelhoef;Friedrich Haag;Thomas T Brehm;Anahita Fathi;Malte Wehmeyer;Jacqueline Jahnke-Triankowski;Leonie Mayer;Armin Hoffmann;Lutz Fischer;Marylyn M Addo;Marc Lütgehetmann;Ansgar W Lohse;Julian Schulze Zur Wiesch;Martina Sterneck - Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022)
  6. Effective viral vector response to SARS-CoV-2 booster vaccination in a patient with rheumatoid arthritis after initial ineffective response to messenger RNA vaccine. - Matthew C Baker;Vamsee Mallajosyula;Mark M Davis;Scott D Boyd;Kari C Nadeau;William H Robinson - Arthritis & rheumatology (Hoboken, N.J.) (2022)
  7. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience. - Yael Peled;Eilon Ram;Jacob Lavee;Amit Segev;Shlomi Matezki;Anat Wieder-Finesod;Rebecca Halperin;Michal Mandelboim;Victoria Indenbaum;Itzchak Levy;Leonid Sternik;Ehud Raanani;Arnon Afek;Yitshak Kreiss;Yaniv Lustig;Galia Rahav - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2022)
  8. Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. - Jorge Hernández-Bello;José Javier Morales-Núñez;Andrea Carolina Machado-Sulbarán;Saúl Alberto Díaz-Pérez;Paola Carolina Torres-Hernández;Paulina Balcázar-Félix;Jesús Alberto Gutiérrez-Brito;José Alvaro Lomelí-Nieto;José Francisco Muñoz-Valle - Vaccines (2021)
  9. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. - Juliet Meir;Muhammad Abbas Abid;Muhammad Bilal Abid - Transplantation and cellular therapy (2021)
  10. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. - Iván Martínez-Baz;Camino Trobajo-Sanmartín;Ana Miqueleiz;Marcela Guevara;Miguel Fernández-Huerta;Cristina Burgui;Itziar Casado;María Eugenia Portillo;Ana Navascués;Carmen Ezpeleta;Jesús Castilla; ; - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2021)

... (206 更多 篇文献)

© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研